JP2017521074A5 - - Google Patents

Download PDF

Info

Publication number
JP2017521074A5
JP2017521074A5 JP2017500932A JP2017500932A JP2017521074A5 JP 2017521074 A5 JP2017521074 A5 JP 2017521074A5 JP 2017500932 A JP2017500932 A JP 2017500932A JP 2017500932 A JP2017500932 A JP 2017500932A JP 2017521074 A5 JP2017521074 A5 JP 2017521074A5
Authority
JP
Japan
Prior art keywords
variant
bmp9
pharmaceutical composition
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017500932A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017521074A (ja
JP6737770B2 (ja
Filing date
Publication date
Priority claimed from GBGB1412290.7A external-priority patent/GB201412290D0/en
Application filed filed Critical
Publication of JP2017521074A publication Critical patent/JP2017521074A/ja
Publication of JP2017521074A5 publication Critical patent/JP2017521074A5/ja
Application granted granted Critical
Publication of JP6737770B2 publication Critical patent/JP6737770B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017500932A 2014-07-10 2015-07-09 骨形成タンパク質の治療上の使用 Active JP6737770B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1412290.7 2014-07-10
GBGB1412290.7A GB201412290D0 (en) 2014-07-10 2014-07-10 Novel use
PCT/GB2015/051989 WO2016005756A1 (en) 2014-07-10 2015-07-09 Therapeutic use of bone morphogenetic proteins

Publications (3)

Publication Number Publication Date
JP2017521074A JP2017521074A (ja) 2017-08-03
JP2017521074A5 true JP2017521074A5 (enExample) 2018-08-23
JP6737770B2 JP6737770B2 (ja) 2020-08-12

Family

ID=51453948

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017500932A Active JP6737770B2 (ja) 2014-07-10 2015-07-09 骨形成タンパク質の治療上の使用

Country Status (22)

Country Link
US (4) US10336800B2 (enExample)
EP (3) EP3669886B1 (enExample)
JP (1) JP6737770B2 (enExample)
KR (2) KR20230049757A (enExample)
CN (1) CN106661094B (enExample)
AU (1) AU2015287397B2 (enExample)
CA (1) CA2954221C (enExample)
CY (2) CY1123011T1 (enExample)
DK (2) DK3669886T3 (enExample)
ES (2) ES2770073T5 (enExample)
GB (1) GB201412290D0 (enExample)
HR (2) HRP20200418T1 (enExample)
HU (2) HUE054512T2 (enExample)
LT (2) LT3166628T (enExample)
MX (2) MX378431B (enExample)
PL (2) PL3166628T5 (enExample)
PT (2) PT3669886T (enExample)
RS (2) RS60181B1 (enExample)
RU (1) RU2733318C2 (enExample)
SI (2) SI3166628T1 (enExample)
SM (2) SMT202100323T1 (enExample)
WO (1) WO2016005756A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201412290D0 (en) 2014-07-10 2014-08-27 Cambridge Entpr Ltd Novel use
GB201603653D0 (en) * 2016-03-02 2016-04-13 Cambridge Entpr Ltd Combination Therapy
AU2018214629A1 (en) * 2017-02-06 2019-08-22 Acceleron Pharma Inc. Compositions and methods for treating heart failure
CA3185525A1 (en) * 2017-11-02 2019-05-09 Bayer Aktiengesellschaft Bispecific antibodies binding alk-1 and bmpr-2
CN107760779B (zh) * 2017-11-03 2020-10-16 中国医学科学院阜外医院 肺动脉高压相关的突变型bmp9基因及其应用
US11485779B2 (en) * 2017-12-12 2022-11-01 Kyowa Kirin Co., Ltd. Anti-BMP10 monoclonal antibody or fragment thereof
CN111939245B (zh) * 2019-05-16 2024-03-01 龚笑海 一种心脏治疗和保护的药物组合物
WO2021113544A1 (en) * 2019-12-03 2021-06-10 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
KR20220021207A (ko) * 2020-08-13 2022-02-22 주식회사 나이벡 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물
WO2023012318A1 (en) * 2021-08-05 2023-02-09 Actelion Pharmaceuticals Ltd Bmp9 variant polypeptides and uses thereof
CN114317604B (zh) * 2022-03-04 2022-06-17 中国医学科学院阜外医院 一种自发性肺动脉高压模型及构建方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US171355A (en) * 1875-12-21 Improvement in driers
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
AU652472B2 (en) * 1991-06-25 1994-08-25 Genetics Institute, Llc BMP-9 compositions
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
KR100231640B1 (ko) 1993-05-12 1999-12-01 토마스 제이 데스로저 Bmp-10 조성물
WO1995024474A1 (en) 1994-03-10 1995-09-14 Human Genome Sciences, Inc. Bone morphogenic protein-10
AU2947395A (en) 1995-06-06 1996-12-24 Human Genome Sciences, Inc. Bone morphogenic protein-10
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
EP1571159A1 (en) † 2004-03-04 2005-09-07 Bayerische Julius-Maximilians-Universität Würzburg Mutein of a bone morphogenetic protein and use thereof
US7741284B2 (en) * 2004-05-12 2010-06-22 Acceleron Pharma Inc. BMP10 propeptides and related methods
WO2006130022A1 (en) 2005-05-30 2006-12-07 Agresearch Limited Modulation of ovulation by agonists and antagonists of bmprii
WO2008014054A2 (en) 2006-07-27 2008-01-31 Centocor, Inc. Bmp-7 variant compositions, methods and uses
EP3181580A1 (en) 2006-11-02 2017-06-21 Acceleron Pharma Inc. Alk1 receptor and ligand antagonists and uses thereof
US20090017019A1 (en) * 2007-06-01 2009-01-15 Wyeth Methods and compositions for modulating bmp-10 activity
US8507501B2 (en) 2008-03-13 2013-08-13 The Brigham And Women's Hospital, Inc. Inhibitors of the BMP signaling pathway
US8999928B2 (en) 2009-04-01 2015-04-07 Indiana University Research And Technology Corporation Methods for treating diseases using a bone morphogenetic protein
WO2010115874A1 (en) 2009-04-07 2010-10-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment and the diagnosis ofpulmonary arterial hypertension
JP6161541B2 (ja) * 2011-02-03 2017-07-12 ゾーマ テクノロジー リミテッド 細菌中の機能的タンパク質発現を向上させるための方法および物質
EP3549952A1 (en) 2011-04-20 2019-10-09 Acceleron Pharma Inc. Endoglin polypeptides and uses thereof
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
WO2014160203A2 (en) 2013-03-14 2014-10-02 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
GB201412290D0 (en) 2014-07-10 2014-08-27 Cambridge Entpr Ltd Novel use
MD3496739T2 (ro) * 2016-07-15 2021-09-30 Acceleron Pharma Inc Compoziții care cuprind polipeptide actriia pentru utilizarea în tratarea hipertensiunii pulmonare
CN107760779B (zh) 2017-11-03 2020-10-16 中国医学科学院阜外医院 肺动脉高压相关的突变型bmp9基因及其应用
KR20220021207A (ko) 2020-08-13 2022-02-22 주식회사 나이벡 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물

Similar Documents

Publication Publication Date Title
JP2017521074A5 (enExample)
RU2017102381A (ru) Терапевтическое применение костных морфогенетических белков
JP7030894B2 (ja) グルカゴン、ｇｌｐ－１及びｇｉｐ受容体のすべてに活性を有する三重活性体
JP2018537087A5 (enExample)
JP2016521688A5 (enExample)
JP2018506286A5 (enExample)
JP2018138049A5 (enExample)
JP2020506701A5 (enExample)
JP2018522563A5 (enExample)
JP2018538356A5 (enExample)
JP2014530010A5 (enExample)
JP2015517489A5 (enExample)
JP2017532966A5 (enExample)
JP2012115277A5 (enExample)
AU2016289492A1 (en) Vaccine against RSV
JP2020023567A5 (enExample)
JP2018537089A5 (enExample)
JP2020172505A5 (enExample)
JP2016513471A5 (enExample)
JPWO2019156137A5 (enExample)
RU2016152151A (ru) Препарат, содержащий фактор viii и пептиды фактора фон виллебранда
JP2017527558A5 (enExample)
JP2017503505A5 (enExample)
JP2019526261A5 (enExample)
JP2019525764A5 (enExample)